Back to results
US 11,047,855 B2Granted
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
AssigneesImmunarray Ltd., Yeda Research and Development Co. Ltd.
InventorsRachel Sorek, Keren Jakobi, Pennina Safer, Anat Reiner-Benaim, Irun R. Cohen
Life of this patent
Estimating the term…
Abstract
Methods and kits for diagnosing or monitoring systemic lupus erythematosus (SLE) in a subject are provided. Particularly, provided is a specific antibody reactivity profile useful in diagnosing or monitoring SLE in a subject.
Claims3
A method of detecting the levels of:
- IgG antibodies reactive to ssDNA, IgG antibodies reactive to U1 snRNP, and IgG antibodies reactive to Sm;
- and
- IgM antibodies reactive to Histone III-S, IgM antibodies reactive to U1 snRNP, and IgM antibodies reactive to an oligonucleotide antigen of the nucleic acid sequence TTA GGG TTA GGG TTA GGG TTA GGG (SEQ ID NO:
- 6, Oligo21),
- in a sample of a subject having or suspected of having systemic lupus erythematosus (SLE), the method comprising:
- (i) obtaining a serum, plasma, or blood sample from the subject;
- (ii) exposing antibodies in the sample to ssDNA, Sm, Histone III-S, U1 snRNP, and Oligo21;
- and
- (iii) detecting in the sample the levels of:
- IgG antibodies reactive to ssDNA, IgG antibodies reactive to U1 snRNP and IgG antibodies reactive to Sm;
- and
- IgM antibodies reactive to Histone III-S, IgM antibodies reactive to U1 snRNP and IgM antibodies reactive to Oligo21,
- by quantifying the amount of antigen-antibody complex formed for each antigen, wherein the amount of antigen-antibody complex is indicative of the level of each respective antibody in said sample.
10 more elements
Dependencies are inferred from the claim text.